LIBERTY ASTHMA TRAVERSE: Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma
Source: View publication →
The TRAVERSE open-label extension study demonstrated that long-term treatment with dupilumab in patients with moderate-to-severe asthma is well-tolerated and provides sustained improvements in asthma exacerbation rates, lung function, and asthma control.
Key Findings
Study Design
Study Limitations
Clinical Significance
The study provides essential long-term evidence for the safety and sustained clinical benefits of dupilumab, a monoclonal antibody targeting IL-4 and IL-13 receptors, supporting its use as a durable maintenance therapy for patients with uncontrolled, moderate-to-severe asthma with a type 2 inflammatory phenotype.
Historical Context
Dupilumab was developed to address unmet needs in patients with uncontrolled type 2 inflammatory asthma. Following successful phase 3 parent trials such as QUEST and VENTURE, which established efficacy over 24-52 weeks, the TRAVERSE open-label extension was necessary to characterize the safety and durability of the clinical response over extended periods (up to 96 weeks), fulfilling regulatory requirements for chronic disease management.
Guided Discussion
High-yield insights from every perspective
What is the primary molecular target of dupilumab, and how does its mechanism of action specifically address the pathophysiology of Type 2 (T2)-high asthma as observed in the TRAVERSE study population?
Key Response
Dupilumab is a fully human monoclonal antibody that binds to the IL-4 receptor alpha (IL-4Rα) subunit. This binding inhibits the signaling of both IL-4 and IL-13, two key cytokines in the Type 2 inflammatory pathway. By blocking these pathways, it reduces eosinophil recruitment, IgE production, and mucus hypersecretion, which are foundational to the airway inflammation and remodeling seen in moderate-to-severe asthma.
In the TRAVERSE study, transient blood eosinophilia was observed in some patients upon initiating dupilumab. How should a clinician manage this laboratory finding, and at what threshold should it prompt further investigation for hypereosinophilic syndromes?
Key Response
Transient eosinophilia is a known pharmacological effect of dupilumab, likely caused by the blockade of IL-4 and IL-13, which prevents eosinophil migration from the blood into the tissues. In most cases, this is asymptomatic and self-limiting. However, clinicians should monitor for clinical signs of eosinophilic granulomatosis with polyangiitis (EGPA) and typically consider further investigation if eosinophil counts exceed 1,500 cells/μL or if systemic symptoms develop.
The TRAVERSE study included patients from both the QUEST and VENTURE trials. How do the long-term FEV1 improvements seen in TRAVERSE inform our understanding of 'fixed airflow obstruction' versus 'reversible inflammation' in the severe asthma phenotype?
Key Response
The sustained improvement in FEV1 over 96 weeks suggests that dupilumab may do more than just provide temporary bronchodilation; it may modulate the underlying inflammatory processes that lead to airway remodeling. For fellows, this highlights the potential for biologics to alter the natural history of lung function decline, though the degree to which 'fixed' obstruction can be reversed remains a point of active investigation in T2-high populations.
Given that the TRAVERSE study demonstrated sustained efficacy for up to 96 weeks, what are the clinical implications for the concept of 'biologic disease remission' and the feasibility of attempting a 'biologic holiday' in patients who achieve stable control?
Key Response
While TRAVERSE shows the drug is safe and effective long-term, it does not provide evidence of a 'cure.' Most experts caution against 'biologic holidays' because the underlying genetic and immunological predisposition to Type 2 inflammation remains. Stopping the biologic often leads to a return of symptoms and a decline in lung function, suggesting that for severe asthma, dupilumab should be viewed as long-term maintenance therapy rather than an induction-to-remission bridge.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TRAVERSE study is an open-label extension (OLE). Critically evaluate the 'healthy survivor effect' as a source of bias in this study design and how it might lead to an overestimation of long-term safety and efficacy compared to a hypothetical continuous randomized controlled trial.
Key Response
OLE designs inherently suffer from selection bias because patients who experienced severe adverse events or lack of efficacy in the parent trials (QUEST/VENTURE) are less likely to enroll in the extension. This 'healthy survivor' cohort may present a more optimistic view of the drug's profile. Researchers must use sensitivity analyses and compare baseline characteristics of the OLE population versus the original intention-to-treat (ITT) population to quantify this bias.
As a reviewer, how would you assess the validity of combining data from the 'placebo-to-dupilumab' group and the 'dupilumab-to-dupilumab' group in TRAVERSE, and what specific statistical adjustments would you require to ensure the 'catch-up' effect doesn't mask long-term waning of efficacy?
Key Response
A journal editor would be concerned with the 'switch' effect. The rapid improvement in the former placebo group (the 'catch-up') provides strong evidence of drug effect but complicates longitudinal trend analysis. A rigorous review would require separate analyses of these cohorts and possibly a longitudinal mixed-effects model to ensure that the rate of improvement or maintenance is consistent across different durations of exposure.
The TRAVERSE data confirms long-term safety and efficacy in patients with moderate-to-severe asthma regardless of baseline eosinophil count. How should this affect the GINA Step 5 recommendations regarding the timing of biologic initiation compared to the use of long-term oral corticosteroids (OCS)?
Key Response
Current GINA and NAEPP guidelines emphasize minimizing OCS use due to systemic toxicity. The TRAVERSE study, particularly the data from the former VENTURE (OCS-dependent) patients, reinforces the role of dupilumab as a potent OCS-sparing agent. This evidence supports a stronger recommendation to initiate biologics earlier in Step 5 (or even Step 4 in specific phenotypes) to prevent the cumulative morbidity associated with chronic OCS use, moving biologics from 'last resort' to 'preferred steroid-sparing' therapy.
Clinical Landscape
Noteworthy Related Trials
LIBERTY ASTHMA DRI
Tested
Dupilumab 200mg or 300mg every 2 weeks
Population
Patients with persistent, moderate-to-severe asthma
Comparator
Placebo
Endpoint
Change from baseline in pre-bronchodilator FEV1 at week 12
LIBERTY ASTHMA QUEST
Tested
Dupilumab 200mg or 300mg every 2 weeks
Population
Patients with uncontrolled, moderate-to-severe asthma
Comparator
Placebo
Endpoint
Annualized rate of severe asthma exacerbations
LIBERTY ASTHMA VENTURE
Tested
Dupilumab 300mg every 2 weeks
Population
Patients with glucocorticoid-dependent severe asthma
Comparator
Placebo
Endpoint
Percentage reduction in daily oral glucocorticoid dose
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis